Eagle Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Eagle Pharmaceuticals

13/03/2023 13:31

* Eagle Pharmaceuticals Inc  EGRX.OQ  reported quarterly
adjusted
earnings of $1.10​​ per share for the quarter ended in December.
The mean expectation of three analysts for the quarter was
for earnings of 83 cents per share.
    * Revenue rose 43.4% to $60.70 million from a year ago;
analysts
expected $64.26 million. 
    * Eagle Pharmaceuticals Inc's reported EPS for the quarter
was 62
cents​.
    * The mean earnings estimate of analysts had fallen by
about 7.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Eagle Pharmaceuticals Inc shares had fallen by 14.3% this
quarter.
    * The company reported quarterly net income of $8.17
million.
    * Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $39.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 13 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      0.83           1.10           Beat
 Sep. 30 2022      0.91           1.12           Beat
 Jun. 30 2022      3.36           1.56           Missed
 Mar. 31 2022      3.88           4.04           Beat